The FDA’s Final Rule on Lab-Developed Tests: What You Need To Know

 

ARUP LabMind Podcast

Jonathan Genzen, MD, PhD, ARUP’s chief medical officer and senior director of governmental affairs, joins Brian Jackson, MD, MS, medical director of Business Development, to answer listeners’ questions on the FDA’s final rule to regulate lab tests, discuss whether the rule will hold up in court, and explain which tests are subject to which requirements.

ARUP Hosts Informational Webinar on the FDA's Final Rule on LDTs

Jonathan Genzen and Jonathan Carr

Summary: The FDA’s final published rule on laboratory-developed tests (LDTs) will result in new oversight that will dramatically shift how clinical laboratories can develop and offer LDTs going forward. In this recorded webinar, ARUP Chief Medical Officer and Senior Director of Governmental Affairs Jonathan Genzen, MD, PhD, and Chief Compliance Officer Jonathan Carr, JD, provide an overview of the requirements included in the final rule and how these requirements differ across certain settings and types of testing. The webinar concludes with a Q&A session in which they share their perspectives on questions submitted by registered attendees.

Additional Webinars

Association for Diagnostics and Laboratory Medicine (ADLM) Webinars Featuring Jonathan Genzen, MD, PhD, MBA, ARUP Chief Medical Officer and Senior Director of Governmental Affairs

The FDA released its final rule to regulate laboratory-developed tests (LDTs) on April 29, 2024. On May 29, 2024, the American Clinical Laboratory Association (ACLA) filed a federal lawsuit challenging the final rule. The Association for Molecular Pathology (AMP) filed a separate lawsuit on August 20, 2024.

Informational Resources

Timeline for Implementation

timeline